Interventional Pain Practice Database

The pain management market is driven by the chronic pain epidemic affecting 50+ million Americans and the ongoing shift away from opioid-based treatment toward interventional procedures. Spinal cord stimulation and other neuromodulation technologies represent the highest-growth segment, with device manufacturers investing heavily in physician education and market development.

Market Overview

The US interventional pain market generates approximately $12 billion annually with strong growth driven by chronic pain prevalence, opioid reduction initiatives, and expanding neuromodulation indications. The total addressable market for vendors includes:

• Neuromodulation devices: $3 billion (spinal cord stimulators, dorsal root ganglion stimulators, peripheral nerve stimulators)
• Intrathecal drug delivery systems: $500 million
• Injectable medications and supplies: $2 billion (steroids, local anesthetics, contrast media, needles, syringes)
• Radiofrequency ablation equipment: $800 million
• Fluoroscopy and imaging equipment: $1.5 billion (C-arms, ultrasound)
• Regenerative medicine products: $1 billion (PRP systems, stem cell products)
• Practice management and billing software: $500 million

Private equity has shown strong interest in pain management, building platforms through acquisitions that create enterprise sales opportunities.

Practice Landscape

• Practice Types:
• **Large interventional pain groups (25%)** - 5-20+ physicians, multiple locations, ASC ownership, high implant volumes
• **Hospital-employed practices (30%)** - Part of health systems or anesthesia departments, access to hospital OR for implants
• **Small groups and solo practitioners (40%)** - 1-4 physicians, high injection volume, may refer implants to specialists
• **Academic medical centers (5%)** - Teaching institutions, complex cases, research programs, device trials

• Ownership Models:
• Strong physician ownership tradition with ASC investment
• Growing PE consolidation creating large regional platforms
• Many practices partner with hospitals for operating room access
• Anesthesia groups often include interventional pain divisions

• Geographic Distribution:
• Practices concentrated in metropolitan areas
• Strong presence in regions with aging populations and manual labor industries
• Workers' compensation and personal injury markets influence regional practice patterns
• Underserved rural areas rely on visiting pain specialists or telemedicine

Key Decision Makers

• Physician Leadership:
• Managing partners and medical directors control vendor relationships and major purchases
• Implanting physicians (SCS, pumps) have strong influence over device selection
• Individual physicians specify needles, medications, and disposables
• Training backgrounds vary (anesthesiology, PM&R, neurology) affecting preferences

• Administrative Leadership:
• Practice administrators manage vendor contracts and supply purchasing
• ASC directors oversee procedure facility operations
• Revenue cycle managers evaluate billing software and coding services
• Compliance officers monitor documentation and regulatory requirements

• Clinical Staff:
• Procedure nurses influence supply and equipment preferences
• Device representatives often present during implant procedures
• Medical assistants affect office supply decisions
• Imaging technologists influence fluoroscopy equipment choices

What's In Our Database

Our interventional pain practice database provides comprehensive data for targeted sales and marketing campaigns:

• Practice Information:
• Practice name, address, phone, fax
• Website and email contacts
• Number of physicians and locations
• ASC ownership and hospital affiliations
• Health system relationships

• Provider Details:
• Pain physician names and credentials
• NPI numbers
• Training background (anesthesiology, PM&R, neurology, other)
• Fellowship training institution
• Years in practice

• Procedure Capabilities:
• Neuromodulation implanting status (SCS, DRG, PNS)
• Intrathecal pump implanting capability
• Regenerative medicine offerings (PRP, stem cells)
• Kyphoplasty/vertebroplasty capability
• Procedure volume estimates

• Technology Profile:
• Fluoroscopy equipment manufacturer and age
• Ultrasound capabilities
• EHR and practice management systems
• Which neuromodulation devices are implanted

Use Cases

• Neuromodulation Device Sales:
• Identify high-volume SCS implanters and target for competitive conversion
• Track which devices practices currently implant for market share analysis
• Reach newly trained physicians entering the implant market
• Target practices expanding into DRG or peripheral nerve stimulation

• Pharmaceutical and Injectable Sales:
• Target high-volume injection practices for steroid and anesthetic sales
• Reach practices for contrast media and imaging supplies
• Identify regenerative medicine practitioners for PRP and biologics
• Market opioid alternatives and non-opioid analgesics

• Capital Equipment:
• Sell C-arms and fluoroscopy systems to practices upgrading equipment
• Market ultrasound systems for peripheral nerve blocks
• Target ASCs for radiofrequency generators and supplies
• Reach practices for procedure tables and monitoring equipment

• Disposable Supplies:
• Target high-volume practices for needles, syringes, and procedure trays
• Sell radiofrequency probes and disposable ablation supplies
• Market specialty needles for specific procedures (epidural, facet, SI joint)
• Reach practices for sterile prep supplies and draping

• Healthcare Services:
• Revenue cycle management for complex pain billing (especially implants)
• Prior authorization services for procedures requiring approval
• Compliance consulting for documentation requirements
• Recruiting services for pain physician shortages

• Market Research:
• Track neuromodulation market share by device manufacturer
• Survey physicians on treatment preferences and unmet needs
• Monitor regenerative medicine adoption trends
• Analyze PE consolidation and its impact on purchasing

Industry Statistics

Market Size - $12 billion annually in the US Number of Practices - ~6,500 interventional pain practices Active Physicians - ~9,000 interventional pain specialists Epidural Injections - 9 million annually Chronic Pain Prevalence - 50 million Americans affected Spinal Cord Stimulator Implants - 50,000+ annually Intrathecal Pump Implants - 10,000+ annually Average Injection Procedure Value - $1,500-$4,000 Average SCS Implant Value - $30,000-$50,000 Opioid Alternative Growth - 15%+ annual increase in interventional procedures RFA Procedures - 500,000+ annually

Why Target Interventional Pain Practices

High Procedure Volume - Pain practices perform millions of injection procedures annually, creating consistent demand for disposables, medications, and imaging supplies.

Premium Implant Market - Neuromodulation devices (SCS, intrathecal pumps) are high-value products with strong margins and physician loyalty once established.

Technology Adoption - Pain physicians adopt new technologies and techniques, including advanced SCS waveforms, DRG stimulation, and regenerative medicine approaches.

Opioid Crisis Response - Regulatory and payer pressure to reduce opioid prescribing drives patients toward interventional pain treatments, expanding the market.

Recurring Revenue - Chronic pain requires ongoing treatment, creating repeat injection patients and device follow-up/reprogramming visits.

ASC Ownership - Many pain practices own procedure facilities, giving them independent purchasing authority and higher procedure throughput.

PE Consolidation - Private equity investment creates large platforms with centralized purchasing, enabling enterprise sales relationships.

Multiple Entry Points - Mix of office visits, injection procedures, and implant surgeries creates diverse opportunities for vendors with varied product portfolios.

Frequently Asked Questions